

Statement of concern

Reports about a highly virulent variant of HIV-1 circulating in the Netherlands is nothing but highly unethical fear-mongering

Carolina Diamandis, Adrian Tudor, Olga Ivanova

Corresponding author

LCG Research
Team of Dr. Carolina Diamandis
Dr. Olga Ivanova
16 Kifissias Avenue
115 26 Athens, Hellenic Republic
www.your-doctor.com

Abstract

Chris Wymant and an entire armada of scientists published a small paper titled "A highly virulent variant of HIV-1 circulating in the Netherlands." The general media have picked up on this and are giving the impression that HIV is now a more dangerous infection. This is not the fault of Wymant and colleagues, but it is highly problematic. This more than 30 years old knowledge, which is now published with big headlines outside the medical press as lurid news, is likely to provoke misunderstandings in the general population. A renewed ostracism and stigmatization of the usual risk groups is now a real prospect. The findings presented in the aforementioned paper should have been addressed exclusively to health professionals and should have better never ended up in the hands of commercial media.

Facts

HIV has long since become a manageable virus, and AIDS has become a rarity in high- and middle-income countries. Reliable prophylaxis is available with PrEP and PEP⁵⁻⁸, and thanks to antiviral treatment, HIV-positive patients have a good chance of living almost the average life expectancy of other members of the society in which they live.¹⁻¹⁵ Like any other virus, HIV has many variants. One of them has been known for decades and was the focus of a recent paper by Wymant et al (2022).¹ In this paper, the focus is on a more virulent HIV variant that probably spread primarily outside Amsterdam in the 1980s and has been known since the early 1990s. With this HIV variant, the most important factor is to detect the infection early and to start therapy very quickly. "VB variant" - for virulent subtype B - is an epidemiologically irrelevant HIV variant whose particular aggressiveness has now been studied in somewhat greater detail. Routine scientific work, nothing more. The results are neither new nor spectacular. Apparently, this HIV variant had evolved long before it was first described in 1992. It contains more than five hundred mutations, and these genetic changes also initially gave the pathogen a noticeable advantage. Presumably, it spread from Amsterdam, but seems to have remained alongside less aggressive strains of the virus. This is because the highly effective antiviral drugs that have been used since 1999 against the development of AIDS as a result of HIV infection also work very well against the VB variant - provided they are administered early enough.

The VB virus may just be faster, it appears to replicate rapidly and, if combated too late, also apparently decimates the T cells that are important for a functioning immune system in a very short time. As part of the British "Beehive" project, the VB viruses of a total of 17 AIDS patients were genetically decoded, of which only one was from Belgium, one from Switzerland and the others from the Netherlands. Outside Amsterdam, additional clusters of VB-infected individuals were identified, bringing the total number to at least 109. According to the researchers, gaps in gene sequencing make it impossible to say exactly how widespread the disease actually is in Europe. Untreated, this variant reaches a viral load within the first two years that is three and a half times that of infected individuals of the same age. Nevertheless, it should be remembered that untreated HIV infections have become a rarity outside of Africa.

The very few patients infected with this HIV variant may develop symptoms earlier than with other variants - if left untreated, which is more theoretical than clinical reality in the years 2022. That untreated patients lose vital immune cells in their blood much more quickly is interesting, but also no news. It's true that other than in different HIV variants, the number of CD4 T cells in the blood decreases in 30- to 39-year-olds up to the critical value within three years after diagnosis - if an individual is infected with the VB variant. It may also be correct that this value can be reached in individual cases without treatment after only nine months. But what is the point? Unfortunately, Wymant and his armada of scientists could not find out which mutations in detail and which molecular mechanisms cause the higher virulence. **However, untreated HIV cases have become a rarity outside Africa, and this has not changed.** Therefore, the results are as interesting as they are **irrelevant** to real clinical life.

Discussion

HIV is an infection that causes significant psychological suffering due to stigma and is still a concern in the field of community medicine.¹⁷⁻²⁰ At the same time, AIDS has not been an unavoidable consequence of HIV infection anymore, for more than two decades.¹⁻¹⁵ Thanks to highly effective antiviral therapies, the absolute majority of HIV patients undergoing treatment only have the infection, they no longer develop the deadly AIDS syndrome. The viral load of most well-treated HIV-positive patients is zero or close to zero. In this case, they are practically no longer infectious.¹⁻¹⁵ **There is no evidence that these facts are not applicable to the HIV variant discussed by Wymant et al.¹**

Prophylactic use of antiviral drugs (PrEP) has even made infection with HIV (all variants) almost impossible, and HIV has always been a vulnerable and not very easily transmissible virus compared with Hepatitis B/C and other viruses. HIV is no longer a killer virus outside Africa. Other infectious diseases such as the mentioned hepatitis B and C and treatment-resistant forms of tuberculosis often remain undetected and are then far more dangerous than a treated HIV infection. Nevertheless, HIV-infected individuals are still suffering from stigmatization, exclusion and discrimination. So puffery and lurid headlines about a supposed new "killer HIV" are likely to reignite stigmas that have just been overcome with a lot of effort.

Never should the paper by Wymant and colleagues have led to headlines in the mass media. The social and psychological damage caused by it is enormous and the negative consequences can hardly be estimated. It is urgently necessary that the group around Wymant revises its paper and classifies it epidemiologically as well as socio-medically correctly in order to reduce the damage caused by mass media hysteria and misinformation.

Conclusion

The HIV variant described in the Wymant paper is neither new nor unknown, it is of academic interest, if at all. Epidemiologically it is irrelevant and clinically no reason for concern. We warn against being frightened by media reports about it. **With regard to HIV, everything is as it has always been since the late 1990s. It is an infection that can be prevented and treated with medication.**

Conflicts of interest

none

References

1. Chris Wymant et al. (2022) A highly virulent variant of HIV-1 circulating in the Netherlands. *Science* 375, 540–545.
2. Taylor BS, Tieu HV, Jones J, Wilkin TJ. CROI 2019: advances in antiretroviral therapy. *Top Antivir Med.* 2019 Apr;27(1):50-68. PMID: 31137003; PMCID: PMC6550357.
3. Ávila-Ríos S, Parkin N, Swanstrom R, Paredes R, Shafer R, Ji H, Kantor R. Next-Generation Sequencing for HIV Drug Resistance Testing: Laboratory, Clinical, and Implementation Considerations. *Viruses.* 2020 Jun 5;12(6):617. doi: 10.3390/v12060617. PMID: 32516949; PMCID: PMC7354449.
4. Simon V, Ho DD, Abdool Karim Q. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. *Lancet.* 2006 Aug 5;368(9534):489-504. doi: 10.1016/S0140-6736(06)69157-5. PMID: 16890836; PMCID: PMC2913538.
5. Spinner CD, Boesecke C, Zink A, Jessen H, Stellbrink HJ, Rockstroh JK, Esser S. HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans. *Infection.* 2016 Apr;44(2):151-8. doi: 10.1007/s15010-015-0850-2. Epub 2015 Oct 15. PMID: 26471511.
6. Eakle R, Venter F, Rees H. Pre-exposure prophylaxis (PrEP) in an era of stalled HIV prevention: Can it change the game? *Retrovirology.* 2018 Apr 2;15(1):29. doi: 10.1186/s12977-018-0408-3. PMID: 29609619; PMCID: PMC5879931.
7. Hillis A, Germain J, Hope V, McVeigh J, Van Hout MC. Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Men Who Have Sex with Men (MSM): A Scoping Review on PrEP Service Delivery and Programming. *AIDS Behav.* 2020 Nov;24(11):3056-3070. doi: 10.1007/s10461-020-02855-9. PMID: 32274670; PMCID: PMC7502438.
8. Phanuphak N, Gulick RM. HIV treatment and prevention 2019: current standards of care. *Curr Opin HIV AIDS.* 2020 Jan;15(1):4-12. PMID: 31658110.
9. Dionne B. Key Principles of Antiretroviral Pharmacology. *Infect Dis Clin North Am.* 2019 Sep;33(3):787-805. doi: 10.1016/j.idc.2019.05.006. PMID: 31395145.
10. Ambrosioni J, Nicolas D, Sued O, Agüero F, Manzardo C, Miro JM. Update on antiretroviral treatment during primary HIV infection. *Expert Rev Anti Infect Ther.* 2014 Jul;12(7):793-807. doi: 10.1586/14787210.2014.913981. Epub 2014 May 7. PMID: 24803105.
11. Kanters S, Vitoria M, Doherty M, Socias ME, Ford N, Forrest JI, Popoff E, Bansback N, Nsanzimana S, Thorlund K, Mills EJ. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis. *Lancet HIV.* 2016 Nov;3(11):e510-e520. doi: 10.1016/S2352-3018(16)30091-1. Epub 2016 Sep 6. PMID: 27658869.
12. Shoko C, Chikobvu D. Determinants of viral load rebound on HIV/AIDS patients receiving antiretroviral therapy: results from South Africa. *Theor Biol Med Model.* 2018 Jul 16;15(1):10. doi: 10.1186/s12976-018-0082-0. PMID: 30008270; PMCID: PMC6047135.
13. Kumarasamy N, Krishnan S. Beyond first-line HIV treatment regimens: the current state of antiretroviral regimens, viral load monitoring, and resistance testing in resource-limited settings. *Curr Opin HIV AIDS.* 2013 Nov;8(6):586-90. PMID: 24100872.

14. Memish ZA, Al-Tawfiq JA, Filemban SM, Qutb S, Fodail A, Ali B, Darweesh M. Antiretroviral therapy, CD4, viral load, and disease stage in HIV patients in Saudi Arabia: a 2001-2013 cross-sectional study. *J Infect Dev Ctries*. 2015 Jul 30;9(7):765-9. doi: 10.3855/jidc.6588. PMID: 26230128.
15. Eriksen J, Carlander C, Albert J, Flamholc L, Gisslén M, Navér L, Svedhem V, Yilmaz A, Sönnernborg A. Antiretroviral treatment for HIV infection: Swedish recommendations 2019. *Infect Dis (Lond)*. 2020 May;52(5):295-329. doi: 10.1080/23744235.2019.1707867. Epub 2020 Jan 11. PMID: 31928282.
16. Ayliffe G; Minimal Access Therapy Decontamination Working Group. Decontamination of minimally invasive surgical endoscopes and accessories. *J Hosp Infect*. 2000 Aug;45(4):263-77. doi: 10.1053/jhin.2000.0767. PMID: 10973743
17. Yuvaraj A, Mahendra VS, Chakrapani V, Yunihastuti E, Santella AJ, Ranauta A, Doughty J. HIV and stigma in the healthcare setting. *Oral Dis*. 2020 Sep;26 Suppl 1:103-111. doi: 10.1111/odi.13585. PMID: 32862542.
18. Chambers LA, Rueda S, Baker DN, Wilson MG, Deutsch R, Raeifar E, Rourke SB; Stigma Review Team. Stigma, HIV and health: a qualitative synthesis. *BMC Public Health*. 2015 Sep 3;15:848. doi: 10.1186/s12889-015-2197-0. PMID: 26334626; PMCID: PMC4557823.
19. Jackson-Best F, Edwards N. Stigma and intersectionality: a systematic review of systematic reviews across HIV/AIDS, mental illness, and physical disability. *BMC Public Health*. 2018 Jul 27;18(1):919. doi: 10.1186/s12889-018-5861-3. PMID: 30049270; PMCID: PMC6062983.
20. Greenwood GL, Wilson A, Bansal GP, Barnhart C, Barr E, Berzon R, Boyce CA, Elwood W, Gamble-George J, Glenshaw M, Henry R, Iida H, Jenkins RA, Lee S, Malekzadeh A, Morris K, Perrin P, Rice E, Sufian M, Weatherspoon D, Whitaker M, Williams M, Zwierski S, Gaist P. HIV-Related Stigma Research as a Priority at the National Institutes of Health. *AIDS Behav*. 2022 Jan;26(Suppl 1):5-26. doi: 10.1007/s10461-021-03260-6. Epub 2021 Apr 22. PMID: 33886010; PMCID: PMC8060687.

Science. Proudly made in Greece.

